A Study of TL-925 as a Treatment for Dry Eye Disease
Status:
Not yet recruiting
Trial end date:
2023-07-18
Target enrollment:
Participant gender:
Summary
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled,
parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED)
will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye
drops administered bilaterally BID.
The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked
treatment.